Robert Samuel

Robert Samuel is a clinical oncology researcher and trainee currently affiliated with the University of Leeds and Leeds Teaching Hospitals NHS Trust. He holds a position as a CRUK Manchester-Leeds Clinical Research Fellow at the Leeds Institute of Medical Research within the Faculty of Medicine and Health. His work bridges clinical practice and academic research in oncology, particularly focusing on radiotherapy, chemoradiotherapy, and cancer outcomes.

• CRUK Manchester-Leeds Clinical Research Fellow, University of Leeds (2021–2024)
• NIHR Academic Clinical Fellow, University of Leeds (2018–2021)
• Clinical Oncology Trainee, Leeds Teaching Hospitals NHS Trust (2018–present)
• Academic Foundation Trainee, Newcastle University (2015–2017)

His research interests center on improving cancer treatment outcomes through advanced imaging, predictive modeling, and molecular understanding. Key areas include:

• Anal squamous cell carcinoma and chemoradiotherapy
• Multimodal imaging (PET-CT, MRI) for response evaluation
• Machine learning and distributed learning for outcome prediction
• Phototherapy in systemic pruritus and dermatological conditions
• Quality assurance in radiotherapy for hematological malignancies

His recent publications demonstrate a strong trend toward integrating data science with clinical oncology, particularly in developing predictive models for radiotherapy toxicity and treatment response. He frequently collaborates across institutions and specialties, indicating a multidisciplinary and translational research approach.

Scientific contributions include multiple peer-reviewed articles in journals such as Radiotherapy and Oncology, British Journal of Dermatology, and Clinical Oncology, as well as presentations at major conferences like RSNA and the European Society for Radiotherapy and Oncology. While no formal awards are listed, his involvement in high-impact consensus projects (e.g., CORMAC-2) highlights recognition in the field.

Robert Samuel actively contributes to both clinical service and research, with a focus on improving patient outcomes through evidence-based innovation. He has been involved in quality improvement projects and audits, particularly in radiotherapy safety and patient recruitment. His work often involves multi-center data and collaborative research networks.

He is part of the Leeds Institute of Medical Research team, contributing to studies on cancer outcomes, radiobiology, and digital health applications in oncology. His research aligns with broader initiatives such as the REQUITE cohort for radiotherapy toxicity prediction.